FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

Durable Efficacy of Alemtuzumab in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy
















































Abstract

Objective:
Evaluate alemtuzumab efficacy/safety over 3 years in the patient subset with highly active relapsing-remitting multiple sclerosis (MS) despite prior therapy.

Background:
In the 2-year, phase 3 CARE-MS II study (NCT00548405), alemtuzumab significantly reduced relapses, disability, and magnetic resonance imaging (MRI) lesions versus subcutaneous interferon beta-1a in patients with highly active disease at baseline (蠅2 relapses in the year before randomization and 蠅1 baseline gadolinium [Gd]-enhancing lesion).

Design/Methods:
Patients received alemtuzumab 12 mg infusions at baseline and month 12, and retreatment if indicated in an ongoing extension study (NCT00930553). Improved Expanded Disability Status Scale (EDSS) score defined as 蠅0.5-point decrease from core study baseline. Sustained accumulation of disability (SAD) is 蠅1-point EDSS score increase (蠅1.5-point if baseline EDSS=0). MS disease freedom was defined as absence of MRI (new Gd-enhancing lesions and new/enlarging T2 lesions) and clinical (SAD and relapse) disease activity.

Results:
Of 103 patients with highly active disease in the CARE-MS II alemtuzumab arm, 92 entered the extension study; 17 (18.5[percnt]) received a third treatment course in Year 3. Annualized relapse rate decreased from 0.33 in the core study to 0.08 in Year 3. EDSS scores were improved (46.2[percnt]) or stable (24.2[percnt]) in 70.3[percnt] of patients through Year 3; 83[percnt] were free from 6-month SAD at Year 3. The majority (64.7[percnt]) was free of MRI activity at Year 3. Yearly median percent change in brain parenchymal fraction slowed from -0.263[percnt] in Year 2 to -0.006[percnt] in Year 3. In Year 3, 19.6[percnt] of patients were MS disease activity-free. No new safety signals emerged in the study group.

Conclusions:
Alemtuzumab demonstrated durable improvements in clinical and MRI outcomes in patients with highly active disease at Year 3, despite most patients receiving their last treatment course 2 years prior. Study Supported by: Genzyme, a Sanofi company, and Bayer Healthcare Pharmaceuticals

Story Source: The above story is based on materials provided by NEUROLOGY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News